FDMT management meeting focuses on 4D-150 phase 3 execution, durability, and the commercialization reimbursement path for wet AMD

Overview

This report is Goldman Sachs' summary of the management meeting with 4D Molecular Therapeutics, focusing on 4D-150's phase 3 clinical execution in wet age-related macular degeneration, injection-burden reduction goals, Medicare reimbursement and pricing, and competitive positioning versus TKI therapies such as OCUL and EYPT. The report also provides a valuation framework and key risks.

Core views

FDMT's core value depends on whether 4D-150 can demonstrate BCVA non-inferiority versus aflibercept 2mg Q8W in the 4FRONT Phase 3 program, while delivering more durable efficacy and materially reducing the need for supplemental injections. Management emphasized safety control, rescue-injection adjudication, cataract management and steroid tapering to reduce confounding factors. Commercially, if 4D-150 can be positioned as a long-duration foundational therapy and secure a workable reimbursement path around the roughly $50K pricing range, there is a substantial market opportunity; however, payer thresholds, clinic buy-and-bill cash-flow pressure, TKI competition and Phase 3 readouts remain major uncertainties.

Analysis framework

The report uses a meeting-minutes format, combining management's statements on clinical trial design, key endpoints, injection burden, payer structure, pricing assumptions and the competitive landscape with Goldman Sachs' DCF valuation and risk framework to assess FDMT's catalysts and commercialization feasibility.

Methodology notes

• Valuation methodsDCF

  12-month target price based on 100% DCF value

  Goldman Sachs' $33 target price is based on DCF valuation, with key assumptions of 21% WACC and 3% terminal growth rate.

• Clinical Trial EvaluationPhase 3 non-inferiority analysis

  BCVA non-inferiority and supplemental injection control

  The 4FRONT studies use BCVA non-inferiority versus aflibercept 2mg Q8W as the primary endpoint and control bias through clearly defined rescue-injection triggers and adjudication processes.

• Commercialization AnalysisUS Medicare buy-and-bill reimbursement

  Medicare Advantage and Fee-for-Service reimbursement pathways

  The report distinguishes between roughly 60% Medicare Advantage and roughly 40% Medicare Fee-for-Service patients, and analyzes the impact of step-through requirements, J-codes, copays and supplemental insurance on commercialization.

• Competitive AnalysisDurability and injection-burden comparison

  Comparison of 4D-150 and TKI therapies on durability and real-world value proposition

  Management believes TKI durability in clinical trials may be around 6-12 months, whereas 4D-150, if it can achieve at least one year or longer efficacy, would be better suited as a foundational treatment.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• FDMT.US

  The report's subject company and owner of the 4D-150 and 4D-175 pipelines

  Strengths

  Has a wet AMD Phase 3 program; Phase 2 data show attractive reductions in injection burden and injection-free rates; COGS/dose is below $1,000, which may support scale and pricing flexibility.

  Weaknesses

  Value depends heavily on Phase 3 clinical success, long-term safety, manufacturing capability and commercialization access.

  Comparison

  Compared with OCUL and EYPT TKI options, 4D-150 is potentially positioned as a longer-duration foundational therapy, but still needs Phase 3 data to prove it.

  Risks

  Clinical failure, inflammation or safety events, regulatory delays, payer blocking, clinic reimbursement pressure, intensifying competition and financing risk.

• 4D-150

  FDMT's core wet AMD candidate, also planned for diabetic macular edema

  Strengths

  Aims to reduce injection burden and provide long-term disease control; the Phase 3 design emphasizes BCVA non-inferiority and strict rescue-injection adjudication.

  Weaknesses

  Commercial value requires validation of long-term durability, real-world efficacy and payer acceptance.

  Comparison

  Versus TKI therapies, management believes 4D-150 may offer at least one year or longer durability and does not require repeat dosing.

  Risks

  If Phase 3 efficacy or safety is below expectations, or if injection-burden reduction is insufficient, differentiation and label value could decline.

• OCUL Axpaxli

  A competitive TKI therapy in wet AMD

  Strengths

  SOL-1 data have been released, and SOL-R non-inferiority trial data are expected in 1Q27.

  Weaknesses

  SOL-1 only compared against single-dose aflibercept, and the commercial and payer case still has uncertainty.

  Comparison

  If TKI efficacy fades in the real world and repeat dosing is needed within intervals close to high-dose Eylea, its differentiation may be questioned.

  Risks

  Excessively high pricing could hurt payer acceptance, while overly low pricing could weaken retina clinic economics.

• 4D-175

  FDMT's geographic atrophy candidate asset

  Strengths

  Has an active IND; if the company chooses to advance it, management says Phase 1 research spending would be low.

  Weaknesses

  The field has a long history of setbacks, and the market may remain skeptical before larger Phase 2 data.

  Comparison

  Compared with the more mature wet AMD program, 4D-175 remains in an earlier development stage.

  Risks

  Early-stage clinical uncertainty remains high, and more data are needed to prove viability.

Key data

• Report date2026-05-19Goldman Sachs equity research report published at 5:04 AM EDT.
• 4FRONT-1 enrollment size523 patientsThe North American study has completed enrollment and randomization, with 480 patients providing 90% power for the 3.9-letter non-inferiority margin.
• 4FRONT-2 enrollment progress2H expected completionThe global study is expected to complete enrollment in 2H, with about 60% treatment-naive and 40% previously treated patients planned.
• Primary endpointBCVA non-inferiority to aflibercept 2mg Q8WBoth Phase 3 studies use this primary endpoint.
• Data readout timing4FRONT-1: 1H27; 4FRONT-2: 2H27The company plans to report data in the first half and second half of 2027, respectively.
• PRISM steroid taper completion rate99% (70/71)70 of 71 patients in the Phase 3 dose group successfully completed local steroid tapering.
• Phase 2 recent-diagnosis subgroup injection-burden reduction92%Recent-diagnosis subgroup data at the Phase 3 dose.
• Phase 2 recent-diagnosis subgroup injection-free rate73%Management believes an 80%/50% reduction in injection burden/injection-free rate is a reasonable commercial hurdle.
• Wet AMD payer mix~60% Medicare Advantage / ~40% Medicare Fee-for-ServiceMedicare Advantage may require step-through; Fee-for-Service can be reimbursed directly by CMS under a J-code.
• Internal base pricing assumption~$50KManagement said its internal model uses about $50K as the base case.
• Payer resistance price point>$90KFeedback from payers suggests therapies priced above $90K may face blocking.
• Potential sales example$1.25bnIf 2,500 U.S. retina physicians each inject an average of 10 patients and there are no bilateral injections, that is roughly equivalent to $1.25bn.
• COGS/dose<$1,000Low unit cost provides flexibility for scale-up and pricing competition.
• Target price$3312-month target price, based on 100% DCF value.
• Valuation assumptions21% WACC; 3% TGRGoldman said both assumptions remain unchanged.

Impact & implications

If 4D-150 succeeds in Phase 3 and shows a meaningful reduction in supplemental injections, FDMT could create a differentiated position in the large ophthalmology market, especially among wet AMD patients who need long-term disease control. Commercial success will depend not only on clinical data, but also on reimbursement evidence, pricing discipline, clinic buy-and-bill execution and real-world performance relative to high-dose Eylea and TKI therapies.

Risks

• Clinical, technical and manufacturing risks: if the program cannot maintain efficacy and safety, or if gene therapy production encounters problems, development or commercialization could be delayed and supply constrained.
• Regulatory risk: failure to obtain regulatory approval in the US or abroad would have a significant negative impact on sales expectations and commercial success.
• Competitive risk: wet AMD and related ophthalmology assets face intense competition, and TKI, high-dose Eylea, biosimilars and other therapies in development could affect pricing and penetration.
• Reimbursement and pricing risk: prices above $90K may encounter payer blocking; Medicare Advantage step-through requirements, patient copays and clinic buy-and-bill reimbursement pressure could affect adoption.
• Financing risk: as a biotechnology company, clinical development and commercialization may require continued funding support.
• Disclosure risk: the company is not inclined to disclose Phase 3 progress in a piecemeal way to avoid potential bias, so interim visibility is limited.

What to watch

• 4FRONT-1 BCVA non-inferiority, rescue injections, inflammation and safety readouts in 1H27.
• Whether the global 4FRONT-2 study completes enrollment as planned in 2H and reports data in 2H27.
• The two-year Phase 2b data planned for 3Q this year, especially whether the recently diagnosed subgroup continues to show favorable trends.
• Whether steroid tapering, inflammation windows and cataract management in Phase 3 are consistent with Phase 2 experience.
• Whether the label can include information related to reduced injection burden.
• Changes in payer feedback on the roughly $50K base pricing assumption and higher pricing bands.
• OCUL Axpaxli SOL-R non-inferiority results in 1Q27 and TKI durability in the real world.
• Progress on DME Phase 3 initiation and whether the 4D-175 geographic atrophy program continues to advance.